

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Proposed Single Technology Appraisal

Clostridium botulinum neurotoxin type A for treating hypersalivation associated with neurological conditions ID1150

Provisional matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> • Merz Pharma UK (clostridium botulinum neurotoxin type A) <p><u>Patient/carer group</u></p> <ul style="list-style-type: none"> • Action Cerebral Palsy • Black Health Agency • Brain and Spine Foundation • Different Strokes • Disability Rights UK • Leonard Cheshire Disability • Motor Neurone Disease Association • MS-UK • Multiple Sclerosis National Therapy Centres • Multiple Sclerosis Society • Multiple Sclerosis Trust • Muslim Council of Britain • Network of Sikh Organisations • Neurological Alliance • Parkinson's UK • Scope • Stroke Association • South Asian Health Foundation • Specialised Healthcare Alliance • The Brain Charity • The Pace Centre <p><u>Professional groups</u></p> <ul style="list-style-type: none"> • Association of British Neurologists • Association of Neuroscience Nurses • British Association of Stroke Physicians • British Geriatrics Society 	<p><u>General</u></p> <ul style="list-style-type: none"> • All Wales Therapeutics and Toxicology Centre • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Medicines and Healthcare Products Regulatory Agency • Multiple Sclerosis Wales • National Association of Primary Care • National Pharmacy Association • Neurological Alliance of Scotland • NHS Alliance • NHS Confederation • Scottish Medicines Consortium • Wales Neurological Alliance • Welsh Health Specialised Services Committee <p><u>Possible comparator companies</u></p> <ul style="list-style-type: none"> • Accord Healthcare (glycopyrronium bromide) • Concordia International (glycopyrronium bromide) • Genus Pharmaceuticals (trihexyphenidyl hydrochloride) • Martindale Pharma (glycopyrronium bromide, transdermal hyoscine hydrobromide)

Provisional matrix for the proposed single technology appraisal of clostridium botulinum neurotoxin type A for treating hypersalivation associated with neurological conditions ID1150

Issue date: January 2018

© National Institute for Health and Care Excellence 2018. All rights reserved.

Page 1 of 3

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> • British Neuropathological Society • British Neuropsychiatry Association • British Paediatric Neurology Association (BPNA) • British Society of Rehabilitative Medicine • Chartered Society of Physiotherapy • Institute of Neurology • Neuromodulation Society of UK and Ireland • Primary Care Neurology Society • Royal College of General Practitioners • Royal College of Nursing • Royal College of Occupational Therapists • Royal College of Pathologists • Royal College of Physicians • Royal College of Speech and Language Therapists • Royal Pharmaceutical Society • Royal Society of Medicine • Therapists in MS • UK Health Forum • UK Clinical Pharmacy Association • UK Multiple Sclerosis Specialist Nurses Association <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health • NHS Canterbury and Coastal CCG • NHS England • NHS High Weald Lewes Havens CCG • Welsh Government 	<ul style="list-style-type: none"> • Proveca (glycopyrronium bromide) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • Brain Research Trust • British Neurological Research Trust • Cochrane Cystic Fibrosis and Genetic Disorders Group • Cochrane Movement Disorders Group • Cochrane Multiple Sclerosis and Rare Diseases of the Central Nervous System Group • Cochrane Stroke Group • MRC Clinical Trials Unit • National Hospital for Neurology and Neurosurgery • National Institute for Health Research • The Cure Parkinson's Trust • The Society for Research in Rehabilitation • UK Parkinson's Disease Consortium • Wellcome Trust <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> • Public Health England • Public Health Wales

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do share it. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTees AND COMMENTATORS

Provisional matrix for the proposed single technology appraisal of clostridium botulinum neurotoxin type A for treating hypersalivation associated with neurological conditions ID1150

Issue date: January 2018

© National Institute for Health and Care Excellence 2018. All rights reserved.

Page 2 of 3

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Determination (FAD).

All non-company consultees are invited to submit a statement¹, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the British National Formulary).

All non-company commentators are invited to nominate clinical specialists or patient experts.

¹Non-company consultees are invited to submit statements relevant to the group they are representing.